Patent · US Active

Recombinant virus products and methods for inhibition of expression of myotilin

US9133482B2 · kind B2 · utility

4Cited by
6References
3Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 21, 2013
Grant dateSep 15, 2015
Priority date
Expiry dateOct 21, 2033

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2750/14143
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

The present invention relates to RNA interference-based methods for inhibiting the expression of the myotilin gene. Recombinant adeno-associated viruses of the invention deliver DNAs encoding microRNAs that knock down the expression of myotilin. The methods have application in the treatment of muscular dystrophies such as Limb Girdle Muscular Dystrophy Type 1A.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.